First Tracks Biotherapeutics Inc. Ordinary Shares (TRAX)

About TRAX

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

104

Website

www.firsttracksbio.com

Fundamentals

1-day range

$41.69$44.61

Market cap

$1.61B

P/E (trailing)

—

P/E (forward)

-11.42

EPS (trailing)

$-4.71

Dividend yield

—

Beta

1.38

Avg. volume

764.2K

Forecasts

9 analyst ratings

First Tracks Biotherapeutics Inc. Ordinary Shares Competitors

Chosen by industry and closest market cap.

• TRAX

  First Tracks Biotherapeutics Inc. Ordinary Shares

  $41.77

  ▼ 6.64%
  Market cap $1.61BP/E —
  $14.72$49.91
• AAPG

  Ascentage Pharma Group International American Depository Shares

  $18.28

  ▼ 2.16%
  Market cap $1.57BP/E —
  $30$91.5
• MRVI

  Maravai LifeSciences Holdings Inc. Class A Common Stock

  $7.67

  ▼ 8.42%
  Market cap $1.66BP/E —
  $2.29$9.42
• INVA

  Innoviva Inc. Common Stock

  $20.97

  ▲ 0.05%
  Market cap $1.53BP/E 4.21
  $16.52$25.15
• BCAX

  Bicara Therapeutics Inc. Common Stock

  $23.42

  ▼ 5.70%
  Market cap $1.69BP/E —
  $10.3$30.99
• SNDX

  Syndax Pharmaceuticals Inc. Common Stock

  $19.55

  ▼ 3.05%
  Market cap $1.70BP/E —
  $12.99$25.59
• PAHC

  Phibro Animal Health Corporation Class A Common Stock

  $37.64

  ▲ 3.55%
  Market cap $1.51BP/E 14.51
  $28.25$60.08

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Barclays Maintains Overweight on First Tracks, Raises Price Target to $65
  benzinga · 8/13/2026
• Barclays Maintains Overweight on First Tracks, Raises Price Target to $65
  Benzinga · 8/13/2026
• First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
  Benzinga · 8/13/2026
• Wedbush Maintains Outperform on First Tracks, Raises Price Target to $70
  Benzinga · 8/13/2026
• Piper Sandler Maintains Overweight on First Tracks, Raises Price Target to $95
  Benzinga · 8/13/2026
• Brinker International To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday
  Benzinga · 8/13/2026
• HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $57
  Benzinga · 8/13/2026
• First Tracks Q2 EPS $(0.95) Up From $(1.47) YoY
  Benzinga · 8/12/2026
• UBS Maintains Buy on First Tracks, Raises Price Target to $65
  Benzinga · 8/10/2026

• STONE BENJAMIN · August 2, 2026 · Grant

  60.5K
• Paul F. Lizzul · August 2, 2026 · Grant

  60.5K
• Daniel Faga · August 2, 2026 · Grant

  193.6K
• Magda Marquet · June 15, 2026 · Option Exercise

  6.0K
• John P. Schmid · June 15, 2026 · Option Exercise

  6.0K
• John A. Orwin · June 15, 2026 · Option Exercise

  6.0K
• Dennis M. Fenton · June 15, 2026 · Option Exercise

  6.0K
• J. Anthony Ware · May 12, 2026 · Grant

  7.0K
• J. Anthony Ware · May 12, 2026 · Grant

  2.5K
• Rita Jain · May 12, 2026 · Grant

  7.0K
• Rita Jain · May 12, 2026 · Grant

  2.5K
• Magda Marquet · May 12, 2026 · Grant

  7.0K
• Magda Marquet · May 12, 2026 · Grant

  2.5K
• John P. Schmid · May 12, 2026 · Grant

  7.0K
• John P. Schmid · May 12, 2026 · Grant

  2.5K